New Program - Magnolia Paws for Compassion - Raises Awareness of the Benefits of Animal Assistance for People With Seizure Disorders
Celebrity Animal Behaviorist Brandon McMillan Joins Eisai, Epilepsy Foundation and 4 Paws for Ability to Shed Light on How Dogs Can Provide Functional and Emotional Support

WOODCLIFF LAKE, N.J., Nov. 6, 2014 /PRNewswire/ -- Eisai Inc. today announced the launch of Magnolia Paws for Compassion, a new program created to raise awareness of the beneficial impact that animals can have on people living with epilepsy and seizure disorders.

Logo

Living with a seizure disorder can be physically challenging and can take an emotional toll on many of the 2.3 million American adults currently living with epilepsy, as well as the 467,711 children and teens living with epilepsy and seizure disorders.1 This can lead to feelings of depression, isolation and loneliness for the person living with the condition, as well as stress, worry and anxiety for family members and caregivers.2,3 Research has proven that the companionship of trained assistance animals helps individuals with seizure disorders feel more relaxed, positive and better able to manage their condition.4

To raise awareness of this important tool to help families coping with seizure disorders, Eisai has partnered with celebrity animal behaviorist and star of the Emmy-nominated CBS television series Lucky Dog, Brandon McMillan, as well as the Epilepsy Foundation and 4 Paws for Ability (4 Paws), a non-profit organization focused on the training and placement of service dogs for children with a variety of conditions, including epilepsy.

"While most people are aware of guide dogs for the blind or deaf, many may not know about the invaluable impact that assistance dogs can have for those households coping with a seizure disorder," said McMillan. "In my decades of experience as an animal trainer, I've seen firsthand the power that animals have to enhance people's lives and this is even more true for those coping with a serious illness."

Service dogs, which include seizure assistance dogs for people with epilepsy and seizure disorders, are rigorously trained to perform tasks for people with various needs. Seizure assistance dogs are typically trained for 12 to 18 months to help with physical challenges and to respond to a seizure in someone who has epilepsy.5

"Living with a seizure disorder can be physically challenging and emotionally isolating for both the person living with the condition and their caregivers," said Nathan Fountain, M.D., Professor of Neurology and Director of the F.E. Dreifuss Comprehensive Epilepsy Program at the University of Virginia School of Medicine.

"Assistance dogs provide functional assistance to help people gain back independence and are trained to bark or alert when a seizure occurs. This can be extremely helpful if seizures occur frequently or during the night when caregivers are asleep," Dr. Fountain said.

In cases where a highly-trained seizure assistance dog is not needed, research has shown that interaction with therapy dogs or even household pets can increase socialization and provide emotional support.4,6  People with seizure disorders or their family members can learn more about how to maximize the benefits of animal assistance in their lives at www.MagnoliaPawsForCompassion.com.

"As part of Eisai's Magnolia program, we look to create support programs that address fundamental unmet patient needs," said Christine Verini, vice president, Corporate Communications and Advocacy at Eisai. "Every person or family coping with an illness faces unique challenges along their journey, but interaction with animals has been shown to be valuable to those coping with a variety of illnesses. We are extremely happy to be working with 4 Paws and the Epilepsy Foundation to increase awareness about the benefits service animals can provide to individuals with epilepsy."

About Epilepsy
Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. According to the Centers for Disease Control and Prevention (CDC), there are about 2.3 million American adults and 467,711 children and teens living with epilepsy and seizure disorders in the United States.1

About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with 48 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The mission of the Epilepsy Foundation is to stop seizures and sudden unexpected death in epilepsy (SUDEP), find a cure and overcome the challenges created by epilepsy through efforts including education, advocacy and research to accelerate ideas into therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit www.epilepsy.com.

About 4 Paws for Ability
4 Paws for Ability is a nonprofit, 501(c)(3) organization whose mission is to place quality service dogs with children with disabilities and veterans who have lost use of limbs or hearing; help with animal rescue, and educate the public regarding use of service dogs in public places. 4 Paws for Ability relies on the generosity of individuals, as well as corporations, and accepts donations for operating expenses, training, food, toys, training supplies, medication, and our building fund. For more information on 4 Paws for Ability, please visit www.4PawsForAbility.org.

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience, oncology, metabolic disorders, vascular, inflammatory and immunological reaction, and antibody-based programs.

Contact: Teresa Cronin
Phone: (201) 949-4326
Email: Teresa_Cronin@eisai.com

References

  1. Epilepsy Basics FAQs. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/epilepsy/basics/faqs.htm#. Updated May 16, 2013. Accessed August 28, 2014.
  2. Marcus, Dawn A., MD. Complimentary Medicine in Cancer Care: Adding a Therapy Dog to the Team. Current Pain Headache Reports (2012) 16:289-291
  3. Urbanski, Beth L, Lazenby, Mark. Distress among Hospitalized Pediatric Cancer Patients Modified By Pet-Therapy Intervention to Improve Quality of Life. Journal of Pediatric Oncology Nursing (2012) 29:272
  4. Seizure Assistance Dog. 4 Paws for Ability Website. http://4pawsforability.org/seizure-assistance-dog/ Accessed November 20, 2013.
  5. Mission and Goals. 4 Paws for Ability Website. http://4pawsforability.org/mission-and-goals/. Accessed November 20, 2013.
  6. Mills, LTC James T., III, SP, Yeager, MAJ Arthur F., SP. Definitions of Animals Used in Healthcare Settings. U.S. Army Medical Department Journal (2012).

 

Eisai logo

Logo - http://photos.prnewswire.com/prnh/20141105/156780LOGO

Logo - http://photos.prnewswire.com/prnh/20120413/MM87168LOGO

 

SOURCE Eisai Inc.

Type Press Release

Date Released November 06, 2014

RECENT RELEASES
Jun 1, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Alerts - Release page
SUBSCRIBE TO OUR NEWS
* Required Fields